In the following video, Motley Fool health care bureau chief Brenton Flynn discusses one of his takeaways from yesterday at the JPMorgan conference: the presentation from Abbott Labs . This is the first time we've heard from the company since it spun off its branded pharmaceuticals business into a new company, AbbVie , at the beginning of the year. Here, Flynn spells out for us Abbott's strategy going forward with two words.
Wondering about that new position in your portfolio? For some Abbott Labs shareholders, the new year brought with it a new company called AbbVie. Formerly Abbott's branded pharmaceuticals business, shares of the new stock were distributed to investors on Jan. 2. To help investors better understand the situation, The Fool has created a brand new premium report on both stocks. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this report by clicking here now.
Editor's note: The video above failed to address a key difference between the Boston Scientific and Abbott Labs stent technologies. Abbott's Absorb stent fully absorbs into the body, while Boston Scientific's Synergy stent retains a metallic implant after a polymer coating absorbs into the body. The Fool regrets the error.
The article The New Abbott's First Words originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.